Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A phase II trial in patients with myelofibrosis primary post-ET or post PV-MF treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation

Improve allo-SCT transplant outcome using a uniform conditioning regimen and pacritinib pretreatment by means of the proportion of patients with a failure within 6 months post-transplant Events that are considered a failure are: primary graft failure secondary graft failure acute GvHD grade 3-4 death whatever the cause is

FieldValue
Modified
2019-12-23
Release Date
2018-06-21
Identifier
0509e156-6032-4bcb-b896-78cd4b79104c
License
Public Access Level
Public